zymocin
a zymo-toxin isolated from Kluyveromyces lactis; active against Saccharomyces cerevisiae
Also Known As:
Kluyveromyces killer toxin; Kluyveromyces lactis toxin; killer toxin (Kluyveromyces)
Networked: 4
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Jablonowski, D:
2 articles
(09/2002 - 11/2001)
|
| 2. | Schaffrath, R:
2 articles
(09/2002 - 11/2001)
|
| 3. | Schaffrath, Raffael:
2 articles
(07/2002 - 05/2002)
|
| 4. | Kitamoto, H K:
1 article
(09/2002)
|
| 5. | Nagase, J:
1 article
(09/2002)
|
| 6. | Jablonowski, Daniel:
1 article
(07/2002)
|
| 7. | Fichtner, Lars:
1 article
(05/2002)
|
| 8. | Fichtner, L:
1 article
(11/2001)
|
| 9. | Frohloff, F:
1 article
(11/2001)
|
| 10. | Stark, M J:
1 article
(11/2001)
|
Related Diseases
| 1. | Hypersensitivity (Allergy)
09/01/2002
- " In a study of zymocin's mode of action, genetic scenarios known to impair transcription or affect the pol II machinery itself were found to elicit hypersensitivity to zymocin. " 09/01/2002
- " The defects at the level of transcriptional elongation displayed by rtf1Delta, ctk1, fcp1 and rpb2 mutants also result in zymocin hypersensitivity. " 05/01/2002
- " Disruption of KTI11 and KTI13 results in the complex tot phenotype observed for the gamma-toxin target site mutants, tot1-7, and includes zymocin resistance, thermosensitivity, hypersensitivity to drugs and slow growth. " 11/01/2001
- " Deletions of both TOT6 and TOT7 result in the complex tot phenotype, including resistance to zymocin, thermosensitivity, slow growth and hypersensitivity towards drugs, thus reinforcing the notion that TOT/Elongator may be crucial in signalling zymocicity. " 09/01/2002
- " Defects in yeast RNA polymerase II transcription elicit hypersensitivity to G1 arrest induced by Kluyveromyces lactis zymocin."
|
|
Related Drugs and Biologics